Compare SMJF & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMJF | CRBU |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 166.6M |
| IPO Year | N/A | 2021 |
| Metric | SMJF | CRBU |
|---|---|---|
| Price | $5.08 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 520.3K | ★ 2.6M |
| Earning Date | 09-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $68.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.38 |
| 52 Week High | $5.80 | $3.53 |
| Indicator | SMJF | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 42.82 |
| Support Level | $4.84 | $1.73 |
| Resistance Level | $5.64 | $2.04 |
| Average True Range (ATR) | 0.26 | 0.13 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 10.00 | 31.82 |
SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.